Press centre

Latest

29 Apr 2020

Venatorx Pharmaceuticals and GARDP partner to develop new antibiotic for hospital acquired infections with limited treatment options

GARDP and Venatorx Pharmaceuticals today announced a collaboration to accelerate the development of cefepime-taniborbactam, an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA).

9 Jul 2020

GARDP welcomes greater investment to accelerate development of new antibiotics

2 Jul 2020

GARDP Welcomes Japan’s Commitment to the Fight Against Most Critical Drug-resistant Infections

19 May 2020

GARDP Joins Forces with University of Queensland to Tackle Serious Bacterial Infections

5 May 2020

GARDP signs MOU with Swiss Biotech BioVersys AG

12 Mar 2020

GARDP partners with Japanese pharmaceutical in pursuit of new antibiotics

5 Dec 2019

GARDP welcomes Germany’s commitment to tackling drug-resistant gonorrhoea

Media contacts

For media inquiries, please contact the GARDP Communications Department:

Phone: +41 22 555 19 90 | Email: communications@gardp.org

Cookie Policy

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.